Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a higher magnesium dose tame severe asthma attacks?

NCT ID NCT07795970

Disease control Sponsor: Thammasat University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This trial tests whether a high-dose continuous infusion of magnesium sulfate can improve outcomes for adults with severe asthma attacks in the emergency department. Participants are randomly assigned to receive either the high-dose infusion or the standard dose. Researchers measure how long patients stay in the ER, whether they need hospital admission, and how well their breathing improves. The goal is to see if the higher dose offers better relief without increasing side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
high-dose intravenous magnesium sulfate
What this could lead to
If it works, a high-dose magnesium infusion could become a standard ER treatment to shorten asthma attacks and reduce hospital admissions.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. High-dose magnesium can cause side effects like low blood pressure or breathing problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years with a known diagnosis of asthma, and * Presence of signs and symptoms consistent with acute asthma exacerbation, including dyspnea, tachypnea, respiratory distress, chest tightness, cough, or wheezing, and * Indication for administration of intravenous magnesium sulfate (MgSO4) Exclusion Criteria: * Patients requiring endotracheal intubation at the time of initial presentation * Hypermagnesemia (more than 2.5 mg/dL) * Known hypersensitivity to magnesium sulfate * Diagnosed or suspected myasthenia gravis or neuromuscular disease * Suspected infection meeting the criteria for patients under investigation (PUI) for coronavirus disease 2019 (COVID-19) * Suspected or confirmed pulmonary tuberculosis * inability to perform pulmonary function testing (spirometry or peak expiratory flow) * known case chronic kidney disease (eGFR \<30 mL/min/1.73 m²), heart block, pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute asthma exacerbation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute asthma Emergencies status asthmaticus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma exacerbation Emergency department High dose Magnesuim sulfate

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.